Boehringer Ingelheim Discontinues Inhaled Cystic Fibrosis Gene Therapy BI 3720931 on February 18, 2026 Boehringer Ingelheim clinical trial termination Cystic Fibrosis gene therapy lentiviral vector +
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant on November 14, 2025 Anticoagulants BMS-986177 clinical trial termination coronary trial Factor XIa inhibitor Janssen Myers Squibb +